Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance

• Published in: Clinical and laboratory haematology 2004-12, Vol.26 (6), p.391-395
• Main Authors: PASSAM, F. H., TSIRAKIS, G., BOULA, A., FRAGOU, A., CONSOLAS, I., ALEGAKIS, A., KYRIAKOU, D. S., ALEXANDRAKIS, M. G.
• Format: Article
• Language: English
• Subjects: Aged; Cell adhesion molecules; Female; Humans; IL-1β; Intercellular Adhesion Molecule-1 - blood; Interleukin-1 - blood; Male; Middle Aged; myelodysplastic syndrome; Myelodysplastic Syndromes - blood; Myelodysplastic Syndromes - diagnosis; Prognosis; sICAM; Solubility; sVCAM; Vascular Cell Adhesion Molecule-1 - blood
• ISSN: 0141-9854; 1365-2257
• DOI: 10.1111/j.1365-2257.2004.00640.x

Summary The aim of this study was to assess circulating soluble intercellular adhesion molecule‐1 (sICAM‐1), soluble vascular cell adhesion molecule‐1 (sVCAM‐1), and interleukin‐1β (IL‐1β) in myelodysplastic syndromes (MDS) in order to evaluate their clinical significance. Seventy patients with untreated MDS [21 refractory anemia (RA), nine RA with ringed sideroblasts (RARS), 17 RA with excess of blasts (RAEB), 11 RAEB in transformation (RAEBt), and 12 chronic myelomonocytic leukemia (CMML)] were included in this study. Serum levels of sICAM, sVCAM, and IL‐1β were determined at diagnosis using commercially available immunoassays. In addition, 15 healthy volunteers were studied as a control group. sICAM, sVCAM, and IL‐1β serum levels were significantly higher in MDS patients in comparison with the control group (P